scholarly journals Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long‐term virological response to entecavir therapy: A randomized trial

2019 ◽  
Vol 91 (7) ◽  
pp. 1295-1300 ◽  
Author(s):  
Ayako Iida‐Ueno ◽  
Masaru Enomoto ◽  
Ritsuzo Kozuka ◽  
Akihiro Tamori ◽  
Norifumi Kawada
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Randomized Trial ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Tenofovir Disoproxil Fumarate

Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long‑term therapy before HBsAg loss in non-cirrhotic HBeAg‑negative chronic hepatitis B

2018 ◽  
Vol 23 (8) ◽  
pp. 711
Author(s):  
George V Papatheodoridis ◽  
Eirini I Rigopoulou ◽  
Margarita Papatheodoridi ◽  
Kalliopi Zachou ◽  
Vassilios Xourafas ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tenofovir Disoproxil Fumarate ◽  
Term Therapy ◽  
Hbsag Loss ◽  
Long Term Therapy ◽  
Negative Chronic Hepatitis

DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B

2018 ◽  
Vol 23 (8) ◽  
pp. 677-685 ◽  
Author(s):  
George V Papatheodoridis ◽  
Eirini I Rigopoulou ◽  
Margarita Papatheodoridi ◽  
Kalliopi Zachou ◽  
Vassilios Xourafas ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Tenofovir Disoproxil Fumarate ◽  
Term Therapy ◽  
Hbsag Loss ◽  
Long Term Therapy ◽  
Negative Chronic Hepatitis

scholarly journals Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yandi Xie ◽  
Rui Jin ◽  
Guangjun Song ◽  
Hui Ma ◽  
Bo Feng
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Hepatitis B Surface Antigen ◽  
Meta Analysis ◽  
Hbsag Clearance ◽  
Virological Relapse ◽  
Antigen Loss

Abstract Background To address the possibility of safe cessation of nucleos(t)ide analogues (NAs) therapy in chronic hepatitis B (CHB) and to identify factors associated with off-NAs virological relapse (VR). Methods A published work search was performed to identify all published studies including patients who ceased NAs and were followed for ≥12 months. A meta-analysis was performed. Results Twenty-six studies involving 2573 patients who discontinued NAs were included. The pooled rate of off-NAs VR was 0.63, being lower in initially hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients (0.57 versus 0.62, P = 0.732). The pooled rates of VR were 0.47, 0.55, 0.61, 0.51, 0.73 and 0.64 at 6, 12, 24, 36, 48 and 60 months after NAs cessation, respectively, being relatively lower in initially HBeAg–positive (0.31, 0.45, 0.55, 0.44, 0.48, 0.52) than HBeAg-negative patients (0.50, 0.55, 0.69, 0.57, 0.53, 0.68) (P = 0.405). The pooled rate of biochemical relapse was 0.44, being lower in initially HBeAg-positive than HBeAg-negative patients (0.43 versus 0.48, P = 0.554). The pooled rates of hepatitis B surface antigen loss and seroconversion was 0.09 and 0.06, respectively. The pooled rates of VR at 12 months after NAs cessation were significant different between duration of on-NAs virological response ≤24 months and >24 months in all patients (0.55 versus 0.41, P = 0.011), initially HBeAg-positive patients (0.59 versus 0.41, P = 0.031), and initially HBeAg-negative patients (0.53 versus 0.37, P = 0.025). Conclusions Safe cessation of NAs therapy seems to be feasible in a substantial proportion of CHB patients. On-NAs virological response >24 months reduces the risk of off-NAs VR. Stopping NAs treatment may have an impact on long-term HBsAg decline and also HBsAg clearance.

Sign in / Sign up

Export Citation Format

Share Document